Editas (EDIT) - Forward P/E Multiple

Official company branding of Editas Medicine, Inc. (EDIT)

Editas Medicine, Inc. (EDIT) specializes in developing innovative medical drugs through genome modification. The business is currently focused on the internal development of its project portfolio using funds from licensing deals, while merger transactions are excluded. The market valuation visualization on GURU.Markets shows that the Forward P/E is 0.00. Its first-mover status in CRISPR technologies allows the firm to independently determine the rules for transferring rights to its key patents.

Market Cap to Projected Earnings: Editas Medicine Inc (EDIT) for 07/04/2022 - 11/18/2026

Metric breakdowns and analytics for Editas Medicine, Inc. (EDIT)

- current price and projected stock value:
- market capitalization indicators:
Analysis of all company metrics:Editas Medicine, Inc.
Signature product of Editas Corp

Editas Medicine, Inc. (EDIT) developments in CRISPR create long-term investment potential through unique patent protection. The company's expected P/E multiple compares current market capitalization with projected net income after taxes. This indicator measures the market's willingness to pay a premium for future cash flows. Analyzing this trend helps identify the risk of overvaluation or undervalued assets. The stability of this ratio confirms the resilience of the business's market value.

Who Editas Medicine, Inc. competes with

Projected Price to Earnings TEM (Tempus AI, Inc)|Qiagen Group (QGEN) - Forward Price to Earnings Multiple|Future Price to Earnings ionispharma.com IONS|Market Cap to Projected Earnings Repligen Corporation (RGEN)|RNA: Projected Price to Earnings|Future Price to Earnings Multiple CRSP (CRISPR Therapeutics Corp)|WGS: Forward P/E Multiple|Projected Price to Earnings Ratio Ultragenyx Corp (RARE)|BEAM (Beam Therapeutics Inc) - Forward P/E Multiple|SRPT: Future Price to Earnings Multiple|Future Price to Earnings Twist Bioscience Corp (TWST)|Projected Price to Earnings 10x Genomics Inc TXG|Intellia Therapeutics, Inc. - Projected Price to Earnings|Future Price to Earnings Multiple STOK|BLFS - Future Price to Earnings|Wave Life Sciences (WVE) - Projected Price to Earnings|MAZE: Forward P/E Multiple|Sionna Therapeutics, Inc. (SION) - Forward P/E Multiple|Future Price to Earnings Prime Medicine, Inc.|TSHA (Taysha) - Market Cap to Future Earnings Ratio|Projected Price to Earnings QURE (uniQure Pharma)|Market Cap to Projected Earnings meiragtx.com|Future Price to Earnings REGENXBIO RGNX|SLDB - Projected Price to Earnings|Ocugen, Inc. - Forward P/E Multiple|PACB (Pacific Biosciences of California) - Price to Future Earnings Ratio|BNTC: Forward P/E Multiple|DSGN - Market Cap to Projected Earnings|RCKT (Rocket Pharma) - Forward P/E Multiple|Future Price to Earnings FDMT|Future Price to Earnings Lexeo Therapeutics, Inc. (LXEO)|Korro Bio Inc. - Price to Future Earnings Ratio|Future Price to Earnings silence-therapeutics.com SLN|PRQR: Price to Future Earnings Ratio|CDXS - Future Price to Earnings|Market Cap to Projected Earnings Sangamo Therapeutics, Inc. SGMO|NAUT (nautilus.bio) - Projected Price to Earnings|Projected Price to Earnings Ratio Metagenomi, Inc. (MGX)|Projected Price to Earnings DTIL|Price to Future Earnings Ratio GBIO (generationbio.com)|Future Price to Earnings Boundless Bio, Inc (BOLD)|Forward P/E Multiple Exicure Inc. (XCUR)|Imunon, Inc. - Projected Price to Earnings|PHIO: Price to Future Earnings Ratio|MBIO - Future Price to Earnings|Price to Expected Earnings Ratio RNAZ|Bionano Genomics, Inc. (BNGO) - Future Price to Earnings|Applied DNA Sciences, Inc. (APDN) - Forward P/E Multiple|BLUE (bluebirdbio.com) - Forward P/E Multiple|Price to Future Earnings Ratio IPA (ImmunoPrecise Antibodies)|Forward P/E Multiple OMGA|Projected Price to Earnings Singular Genomics Systems OMIC|Forward P/E Multiple RGLS (regulusrx.com)|Syros Pharmaceuticals Inc. (SYRS) - Projected Price to Earnings Ratio|TBIO: Projected Price to Earnings|Future Price to Earnings Multiple TCON (TRACON)|UBX: Forward P/E Multiple